Sarepta announces updated data from eteplirsen Phase IIb study Sarepta Therapeutics announced updated data from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy, or DMD.
http://www.theflyonthewall.com/permalinks/entry.php/GSK;SRPTid1812197/GSK;SRPT-GlaxoSmithKline-to-present-data-on-DMD-treatment-on-Thursday-Bloomberg-says
http://www.theflyonthewall.com/permalinks/entry.php/GSK;SRPTid1812197/GSK;SRPT-GlaxoSmithKline-to-present-data-on-DMD-treatment-on-Thursday-Bloomberg-says
No comments:
Post a Comment